TC-325 hemostatic powder in the management of upper gastrointestinal malignant bleeding: a randomized controlled trial.

ABSTRACT: Background and study aims  Upper gastrointestinal bleeding (UGIB) from malignancy is associated with high rebleeding and mortality rates. Recently, TC-325 powder has shown promising results in the treatment of UGIB, including malignant bleeding. The aim of this study was to compare the efficacy of TC-325 versus best clinical management. Patients and methods  From August 2016 to February 2020, all patients with evidence of UGIB from malignancy were randomized to receive TC-325 therapy or control group, in which endoscopic treatment was not mandatory. Exclusion criteria were hemoglobin drop without overt bleeding and UGIB from non-tumor origin. The primary outcome was 30-day mortality. Secondary outcomes were 30-day rebleeding, blood transfusion and length of hospital stay.

SUBMITTER: Martins BC 

PROVIDER: S-EPMC9576337 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature